Augustin N, Schreiber C, Wottke M, Meisner H
Klinik für Herz- und Gefässchirurgie, Deutsches Herzzentrum an der Technischen Universität München.
Herz. 1998 Aug;23(5):287-92. doi: 10.1007/BF03044359.
Ebstein's anomaly is a complex malformation of the tricuspid valve where the hinges of the septal and/or posterior leaflets are displaced downward into the right ventricle. The leaflets show variable deformations. In general, the anterior leaflet is enlarged. For those patients who have only mild symptoms, medical management is recommended, but operative treatment is indicated if progressive deterioration is evident. The timing of the surgical intervention is still a matter of controversy, especially since the results of surgical treatment were substantially improved by further development of repair techniques. Between 1974 and August, 1997, 69 patients with Ebstein's anomaly underwent surgical repair. In 65 patients (94.2%) tricuspid valvuloplasty was feasible, mainly by creating a monocusp valve with the "single-stitch technique", developed in our clinic by F. Sebening. Four patients required primary valve replacement with a bioprosthesis. Ten reoperations (14.5%) were necessary: 6 repeat valvuloplasties, 4 valve replacements. There were 2 hospital deaths (2.9%), the late mortality was 8.7% (6 patients). Since 1992, our valvuloplasties have been evaluated by intraoperative transesophageal echocardiography (TEE). Follow-up was obtained in 58 patients (95%) over a period of 4 months to 21.0 years (median 5.3 years, mean 7.6 years). The actuarial survival rate (Kaplan-Meier) was 96.5% +/- 2.4% at 1 year and 83.3% +/- 5.6% at 21 years. Pre-operatively, the majority of patients were in New York Heart Association functional Class III. At follow-up evaluation, nearly all patients showed substantial improvement of their pre-operative status, 94.8% were in NYHA Class I or II. Doppler echocardiographic studies demonstrated good tricuspid valve function in most patients. The valvuloplasty developed in our hospital using a single-stitch technique is a rewarding operation, which yields good long-term results. An analysis of the postoperative deaths revealed that all patients but one suffered from endstage cardiac disease and had a cardio-thoracic ratio greater than 0.65. This supports the importance of surgical intervention in time. In our opinion, operation is even indicated for those patients in functional Class II who reveal clinical deterioration.
埃布斯坦畸形是一种三尖瓣的复杂畸形,其中隔叶和/或后叶的瓣叶铰链向下移位至右心室。瓣叶呈现出不同程度的变形。一般来说,前叶会增大。对于那些仅有轻度症状的患者,建议进行药物治疗,但如果病情明显进展性恶化,则需进行手术治疗。手术干预的时机仍然存在争议,尤其是随着修复技术的进一步发展,手术治疗的效果有了显著改善。1974年至1997年8月期间,69例埃布斯坦畸形患者接受了手术修复。65例患者(94.2%)可行三尖瓣成形术,主要采用我们诊所由F. 塞贝宁研发的“单针法”构建单叶瓣。4例患者需要初次使用生物假体进行瓣膜置换。需要进行10次再次手术(14.5%):6次重复瓣膜成形术,4次瓣膜置换。有2例住院死亡(2.9%),晚期死亡率为8.7%(6例患者)。自1992年以来,我们的瓣膜成形术通过术中经食管超声心动图(TEE)进行评估。58例患者(95%)获得了随访,随访时间为4个月至21.0年(中位数5.3年,平均7.6年)。1年时的精算生存率(Kaplan-Meier法)为96.5%±2.4%,21年时为83.3%±5.6%。术前,大多数患者处于纽约心脏协会功能分级III级。在随访评估中,几乎所有患者术前状况都有显著改善,94.8%处于纽约心脏协会I级或II级。多普勒超声心动图研究显示大多数患者三尖瓣功能良好。我们医院采用单针法研发的瓣膜成形术是一种值得开展的手术,能产生良好的长期效果。对术后死亡病例的分析表明,除1例患者外,所有患者均患有终末期心脏病,心胸比率大于0.65。这支持了及时进行手术干预的重要性。我们认为,对于那些功能分级为II级且出现临床病情恶化的患者也应进行手术。